MedPage Today April 25, 2024
Associated Press

— Gym and diet food companies look to muscle in

Ever since college, Brad Jobling struggled with his weight, fluctuating between a low of 155 pounds when he was in his 30s to as high as 220. He spent a decade tracking calories on WeightWatchers, but the pounds he dropped always crept back onto his 5-foot-5-inch frame.

A little over a year ago, the 58-year-old Manhattan resident went on a new weight-loss drug called semaglutide (Wegovy). He’s lost 30 pounds, and has started eating healthier food and exercising — the habits behind many commercial diet plans and decades of conventional wisdom on sustainable weight loss.

Yet Jobling’s experience also has altered his perspective on dieting. He now sees obesity as...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider
Akiko Iwasaki: The Immunology of Covid and the Future
Novartis to acquire radiopharmaceutical firm Mariana Oncology for up to $1.75B
GLP-1 Agonists May One Day Treat Prostate Cancer
Amgen shares soar as executives outline obesity drug push
BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders

Share This Article